Inventra 7 HF-T QPMR conditional CRT-D
The Inventra 7 CRT-D series with BIOTRONIK Home Monitoring®, ProMRI®, CLS, 45 J ultra-high energy and quadripolar LV pacing enables multiple left-ventricular pacing and sensing configurations for CRT management, providing powerful therapy for patients at risk of high defibrillation thresholds (DFTs). This series offers innovative solutions that improve quality of life and reduce mortality in heart failure patients1.
- BIOTRONIK Home Monitoring enables wireless patient monitoring, including Home Monitoring-supported follow-ups with remote scheduling, for the early detection of clinical and device-related events
- ProMRI® technology enables patients access to MRI scans under certain conditions2
- Closed Loop Stimulation (CLS) provides unique physiological rate response modulation during episodes of physical and emotional activity or stress
- 45 J shock energy improves patient safety for successful defibrillation
- Quadripolar LV pacing enables multiple left-ventricular pacing and sensing configurations for CRT management
- The Heart Failure Monitor enables the early detection of changes in patients’ heart failure conditions with the continuous monitoring of clinical parameters
- The DF4 connector simplifies and shortens the implantation procedure and reduces material in the device pocket
- Automatic atrial therapy delivers atrial therapies to automatically treat AT/AF episodes
- Extended device longevity with battery and energy efficient technology
BIOTRONK CRT-Ds provide up to 7.5 years of longevity, reducing device replacements and their associated risks.
BIOTRONIK CRT-Ds provide automatic, daily implant-based remote monitoring, leading to a more than 50% reduction in mortality for heart failure patients, as proven by the IN-TIME trial.1
BIOTRONIK CRT-Ds feature full-body MRI scan options2 to improve the diagnosis of non-cardiac comorbidities in heart failure patients.
BIOTRONIK Home Monitoring provides reliable daily transmissions so you can treat heart failure patients according to ESC guidelines.3 Earlier detection of clinical problems reduces inappropriate shocks3 and increases patients lifetimes1
BIOTRONIK CRT-Ds with Home Monitoring reduce the number of patients who receive inappropriate shocks by 52%, as proven by the ECOST trial4
Supporting Physiological Pacing
BIOTRONIK CRT-Ds with Closed Loop Stimulation adapt patients' heart rates in the most physiological way, promoting intrinsic rhythm as much as possible and ensuring effective pacing in all chambers.
Flexibility in LV Pacing
MultiSelect LV offers electronic repositioning options to select the optimal stimulation site, manage phrenic nerve stimulation and achieve an excellent pacing threshold to improve CRT therapy.
Powerful, Ultra-High Energy
The most powerful technology and therapy available to ensure effective defibrillation and protect the safety of high-risk patients. A maximum energy of 45 J at the first shock revives patients on the first attempt.
BIOTRONIK Home Monitoring
BIOTRONIK Home Monitoring is a remote monitoring service available with cardiac monitors, pacemakers, implantable defibrillators (ICDs) and cardiac resynchronization therapy (CRT) systems. Home Monitoring allows physicians to continuously and reliably survey patients’ device and physiological condition, and alerts responsible healthcare staff of acute health changes within 24 hours.
Closed Loop Stimulation
CLS is a unique physiological rate-adaptive technology. The feature is able to determine the appropriate heart rate response during episodes of physical and emotional activity or stress.
BIOTRONIK in CRT
BIOTRONIK is saving lives
1 Hindricks G, Taborsky M, Glikson M, et al. Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial. The Lancet. 2014; 384 (9943): 583–590.
2 See ProMRI manual for details and specific conditions
3 Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal. 2013; 34: 2281–2329.
4 Guédon-Moreau L, Lacroix D, Sadoul N, et al. A randomized study of remote follow-up of implantable defibrillators: Safety and efficacy report of the ECOST trial. Eur Heart J. 2013; 34: 605–614.